DK3464338T3 - Modificeret rna, der koder for vegf-a-polypeptider, formuleringer og anvendelser forbundet dermed - Google Patents

Modificeret rna, der koder for vegf-a-polypeptider, formuleringer og anvendelser forbundet dermed Download PDF

Info

Publication number
DK3464338T3
DK3464338T3 DK17734885.1T DK17734885T DK3464338T3 DK 3464338 T3 DK3464338 T3 DK 3464338T3 DK 17734885 T DK17734885 T DK 17734885T DK 3464338 T3 DK3464338 T3 DK 3464338T3
Authority
DK
Denmark
Prior art keywords
polypeptides
formulations
modified rna
rna encoding
encoding vegf
Prior art date
Application number
DK17734885.1T
Other languages
English (en)
Inventor
Jonathan Clarke
Leif Karlsson Parinder
Danielson Regina Desirée Fritsche
Kenny Mikael Hansson
Li Ming Gan
Ann-Charlotte Eva Egnell
Kenneth Randall Chien
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Application granted granted Critical
Publication of DK3464338T3 publication Critical patent/DK3464338T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
DK17734885.1T 2016-06-07 2017-06-06 Modificeret rna, der koder for vegf-a-polypeptider, formuleringer og anvendelser forbundet dermed DK3464338T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662346979P 2016-06-07 2016-06-07
US201662411091P 2016-10-21 2016-10-21
US201662432005P 2016-12-09 2016-12-09
PCT/US2017/036188 WO2017214175A1 (en) 2016-06-07 2017-06-06 Modified rna encoding vegf-a polypeptides, formulations, and uses relating thereto

Publications (1)

Publication Number Publication Date
DK3464338T3 true DK3464338T3 (da) 2021-10-18

Family

ID=59270113

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17734885.1T DK3464338T3 (da) 2016-06-07 2017-06-06 Modificeret rna, der koder for vegf-a-polypeptider, formuleringer og anvendelser forbundet dermed

Country Status (24)

Country Link
US (1) US11866475B2 (da)
EP (2) EP3464338B1 (da)
JP (3) JP6859369B2 (da)
KR (4) KR102376245B1 (da)
CN (2) CN116606861A (da)
AU (2) AU2017277277B2 (da)
CA (1) CA3026500A1 (da)
CY (1) CY1124667T1 (da)
DK (1) DK3464338T3 (da)
ES (1) ES2895421T3 (da)
HR (1) HRP20211569T1 (da)
HU (1) HUE056055T2 (da)
IL (1) IL263370A (da)
LT (1) LT3464338T (da)
MA (1) MA45172B1 (da)
MX (1) MX2018015110A (da)
PL (1) PL3464338T3 (da)
PT (1) PT3464338T (da)
RS (1) RS62556B1 (da)
RU (1) RU2756313C2 (da)
SG (2) SG11201810816QA (da)
SI (1) SI3464338T1 (da)
TW (2) TWI818375B (da)
WO (1) WO2017214175A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116606861A (zh) 2016-06-07 2023-08-18 摩登纳特斯有限公司 编码vegf-a多肽的经修饰的rna、配制品和关于它们的用途
US11628227B2 (en) * 2017-07-05 2023-04-18 Wisconsin Alumni Research Foundation Mineral coated microparticles for gene delivery in chronic wound therapy
KR20200081420A (ko) 2017-10-31 2020-07-07 모더나티엑스, 인크. Vegf-a 폴리펩타이드를 인코딩하는 변형된 rna를 운반하기 위한 지질 나노입자
JP2022532075A (ja) * 2019-05-08 2022-07-13 アストラゼネカ アクチボラグ Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａを送達するために脂質ナノ粒子を使用する方法、及びこの脂質ナノ粒子を含む医薬組成物
JP7345888B2 (ja) * 2021-06-17 2023-09-19 株式会社ニューギン 遊技機
WO2023061985A2 (en) * 2021-10-12 2023-04-20 Modernatx, Inc. Compositions comprising modified rna encoding vegf-a and methods of use
WO2023084013A1 (en) * 2021-11-12 2023-05-19 Modernatx, Inc. Compositions comprising modified rna encoding vegf-a and methods of use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004035227A1 (de) * 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
WO2006086798A2 (en) 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving mda-7 for the treatment of cancer
JP5705127B2 (ja) 2008-12-03 2015-04-22 アモーサイト インコーポレイテッド 梗塞領域灌流改善組成物および血管損傷修復の方法
US8927511B2 (en) 2008-12-04 2015-01-06 Curna, Inc. Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
WO2011069529A1 (en) * 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
AU2011358150B2 (en) 2010-12-16 2016-11-03 Sprna Gmbh Pharmaceutical composition consisting of RNA having alkali metal as counter ion and formulated with dications
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP2694660B1 (en) 2011-04-03 2018-08-08 The General Hospital Corporation Efficient protein expression in vivo using modified rna (mod-rna)
WO2013090648A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
CA2859691A1 (en) 2011-12-21 2013-06-27 Moderna Therapeutics, Inc. Methods of increasing the viability or longevity of an organ or organ explant
US20140275229A1 (en) * 2012-04-02 2014-09-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
JP2015516143A (ja) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
WO2014152211A1 (en) * 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
CN105451779A (zh) 2013-08-21 2016-03-30 库瑞瓦格股份公司 增加rna编码蛋白表达的方法
CA2931986A1 (en) * 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
US20180085474A1 (en) 2015-01-23 2018-03-29 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
HUE057613T2 (hu) 2015-09-17 2022-05-28 Modernatx Inc Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
CN116606861A (zh) 2016-06-07 2023-08-18 摩登纳特斯有限公司 编码vegf-a多肽的经修饰的rna、配制品和关于它们的用途
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
MX2016016339A (es) 2016-12-09 2018-06-08 Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A S De C V Composicion coadyuvante de un factor de crecimiento y un neuropeptido para acelerar la cicatrizacion de heridas y la repitelizacion de organos.
KR20200081420A (ko) 2017-10-31 2020-07-07 모더나티엑스, 인크. Vegf-a 폴리펩타이드를 인코딩하는 변형된 rna를 운반하기 위한 지질 나노입자
EP3965797A1 (en) 2019-05-08 2022-03-16 AstraZeneca AB Compositions for skin and wounds and methods of use thereof

Also Published As

Publication number Publication date
JP2019521976A (ja) 2019-08-08
PL3464338T3 (pl) 2021-12-27
KR102494499B1 (ko) 2023-01-31
KR20230107891A (ko) 2023-07-18
AU2023208200A1 (en) 2023-08-17
TWI752036B (zh) 2022-01-11
KR20230019505A (ko) 2023-02-08
JP2021100961A (ja) 2021-07-08
IL263370A (en) 2018-12-31
CA3026500A1 (en) 2017-12-14
AU2017277277B2 (en) 2023-05-04
TW202218670A (zh) 2022-05-16
CN116606861A (zh) 2023-08-18
US11866475B2 (en) 2024-01-09
RS62556B1 (sr) 2021-12-31
RU2756313C2 (ru) 2021-09-29
AU2017277277A1 (en) 2019-01-03
EP3464338A1 (en) 2019-04-10
TWI818375B (zh) 2023-10-11
RU2018147229A (ru) 2020-07-10
RU2018147229A3 (da) 2020-09-23
JP7167226B2 (ja) 2022-11-08
CN109790207B (zh) 2023-06-20
LT3464338T (lt) 2022-01-10
KR102552543B1 (ko) 2023-07-06
KR102376245B1 (ko) 2022-03-21
MA45172B1 (fr) 2021-11-30
EP3971204A1 (en) 2022-03-23
ES2895421T3 (es) 2022-02-21
HRP20211569T1 (hr) 2022-01-21
CN109790207A (zh) 2019-05-21
PT3464338T (pt) 2021-10-19
SG11201810816QA (en) 2018-12-28
MA45172A (fr) 2019-04-10
TW201808325A (zh) 2018-03-16
WO2017214175A1 (en) 2017-12-14
SG10202012175YA (en) 2021-01-28
US20200407411A1 (en) 2020-12-31
KR20190039066A (ko) 2019-04-10
HUE056055T2 (hu) 2022-01-28
CY1124667T1 (el) 2022-07-22
EP3464338B1 (en) 2021-07-21
KR20220038819A (ko) 2022-03-29
SI3464338T1 (sl) 2022-02-28
JP2023011733A (ja) 2023-01-24
MX2018015110A (es) 2019-09-06
JP6859369B2 (ja) 2021-04-14

Similar Documents

Publication Publication Date Title
DK3347472T3 (da) Sammensætninger som indeholder cyp76ad1- clade polypeptider og anvendelse heraf.
DK3703658T3 (da) Lipidnanopartikler til administration af modificeret rna, der koder for et vegf-a-polypeptid
DK3458083T3 (da) Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf
DK3356390T3 (da) Fremgangsmåder og sammensætninger til virusvektorer, der undgår antistoffer
DK3464338T3 (da) Modificeret rna, der koder for vegf-a-polypeptider, formuleringer og anvendelser forbundet dermed
DK3407888T3 (da) Pyridopyrroloquinoxalinforbindelser, deres sammensætninger og anvendelser
DK3676297T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK3412302T3 (da) Modificerede fgf-21-polypeptider og anvendelser deraf
DK3268470T3 (da) Transposasepolypeptider og anvendelser deraf
DK3107938T3 (da) Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf
DK3262008T3 (da) Partikelformede sammensætninger til dannelse af geopolymerer, deres anvendelse og fremgangsmåder til dannelse af geopolymere dermed
DK3154594T3 (da) Fap-aktiverede, terapeutiske midler og anvendelser i forbindelser dermed
DK3161124T3 (da) Endofytter, associerede sammensætninger og fremgangsmåder til anvendelse deraf
DK3297637T3 (da) Benzen-1,3,5-tricarboxamidderivater og anvendelser deraf
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
DK3425046T3 (da) Herbicidtolerant protein, kodningsgen og anvendelse deraf
DK3408326T3 (da) Elastomerartikler, sammensætninger og fremgangsmåder til fremstilling deraf
DK3275895T3 (da) Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf
DK3580561T3 (da) Hla-baserede metoder, sammensætninger og anvendelse heraf
DK3368655T3 (da) Forbedret proteinekspression og fremgangsmåder dertil
DK3145945T3 (da) Hidtil ukendte specifikt bindende polypeptider og anvendelser deraf
DK3137168T3 (da) Substituerede 4-phenylpiperidiner, deres fremstilling og anvendelse
DK3233192T3 (da) Sammensætninger og fremgangsmåder til målrettet cytokinindgivelse
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf